# Paclitaxel-Model
Whole-body PBPK model of paclitaxel

<p align="center">
  <img src="Paclitaxel.png">
</p>

## Repository files

Within this repository, we distribute a whole-body PBPK model of  Paclitaxel, that has been developed using clinical studies in adults and evaluated for its predictive performance of GFR mediated clearance after oral administration in children. 

The PK-Sim project file contains simulations of all published clinical studies employed during model establishment [[1-4](#reference)] and for model predictions in pediatrics [[6-8](#reference)], including the respective observed data digitized.

## Code of conduct

Everyone interacting in the Open Systems Pharmacology community  (codebases, issue trackers, chat rooms, mailing lists etc...) is  expected to follow the Open Systems Pharmacology [code of conduct](https://github.com/Open-Systems-Pharmacology/Suite/blob/master/CODE_OF_CONDUCT.md#contributor-covenant-code-of-conduct).

## Contribution

We encourage contribution to the Open Systems Pharmacology community. Before getting started please read the [contribution guidelines](https://github.com/Open-Systems-Pharmacology/Suite/blob/master/CONTRIBUTING.md#ways-to-contribute). If you are contributing code, please be familiar with the [coding standard](https://github.com/Open-Systems-Pharmacology/Suite/blob/master/CODING_STANDARDS.md#visual-studio-settings).

## License

The model code is distributed under the [GPLv2 License](https://github.com/Open-Systems-Pharmacology/Suite/blob/develop/LICENSE).

## Reference

[1] [Diamond JR, Wu B, Agarwal N, Bowles DW, Lam ET, Werner TL, Rasmussen E, Gamelin E, Soto F, Friberg G, Sun YN, Sharma S. Pharmacokinetic drug-drug interaction study of the angiopoietin-1/angiopoietin-2-inhibiting peptibody trebananib (AMG 386) and paclitaxel in patients with advanced solid tumors. Invest New Drugs. 2015 Jun;33(3):691-9. doi: 10.1007/s10637-015-0236-4. Epub 2015 Apr 21.](https://link.springer.com/article/10.1007%2Fs10637-015-0236-4)

[2] [Huizing MT, Keung AC, Rosing H, van der Kuij V, ten Bokkel Huinink WW, Mandjes IM, Dubbelman AC, Pinedo HM, Beijnen JH. Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients. J Clin Oncol. 1993 Nov;11(11):2127-35.](https://ascopubs.org/doi/abs/10.1200/JCO.1993.11.11.2127)

[3] [Huizing MT, Vermorken JB, Rosing H, ten Bokkel Huinink WW, Mandjes I, Pinedo HM, Beijnen JH. Pharmacokinetics of paclitaxel and three major metabolites in patients with advanced breast carcinoma refractory to anthracycline therapy treated with a 3-hour paclitaxel infusion: a European Cancer Centre (ECC) trial. Ann Oncol. 1995 Sep;6(7):699-704](https://www.ncbi.nlm.nih.gov/pubmed/8664192)

[4] [Ibrahim NK, Desai N, Legha S, Soon-Shiong P, Theriault RL, Rivera E, Esmaeli B, Ring SE, Bedikian A, Hortobagyi GN, Ellerhorst JA. Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res. 2002 May;8(5):1038-44.](http://clincancerres.aacrjournals.org/content/8/5/1038.long)

[5] [Sparreboom A, Scripture CD, Trieu V, Williams PJ, De T, Yang A, Beals B, Figg WD, Hawkins M, Desai N. Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol).Clin Cancer Res. 2005 Jun 1;11(11):4136-43.](http://clincancerres.aacrjournals.org/content/11/11/4136.long)

[6] [Doz F, Gentet JC, Pein F, Frappaz D, Chastagner P, Moretti S, Vassal G, Arditti J, Tellingen OV, Iliadis A, Catalin J. Phase I trial and pharmacological study of a 3-hour paclitaxel infusion in children with refractory solid tumours: a SFOP study. Br J Cancer. 2001 Mar 2;84(5):604-10.](https://www.nature.com/articles/6691637)

[7] [Horton TM, Ames MM, Reid JM, Krailo MD, Pendergrass T, Mosher R, Reaman GH, Seibel NL; Children's Oncology Group. A Phase 1 and pharmacokinetic clinical trial of paclitaxel for the treatment of refractory leukemia in children: a Children's Oncology Group study. Pediatr Blood Cancer. 2008 Apr;50(4):788-92.](https://onlinelibrary.wiley.com/doi/full/10.1002/pbc.21310)

[8] [Sonnichsen DS, Hurwitz CA, Pratt CB, Shuster JJ, Relling MV. Saturable pharmacokinetics and paclitaxel pharmacodynamics in children with solid tumors. J Clin Oncol. 1994 Mar;12(3):532-8.](https://ascopubs.org/doi/abs/10.1200/JCO.1994.12.3.532)

